NasdaqGM:PTGXBiotechs
How Investors Are Reacting To Protagonist Therapeutics (PTGX) Rusfertide’s Pivotal Phase 3 VERIFY Results
Protagonist Therapeutics and collaboration partner Takeda recently reported 52-week data from the pivotal Phase 3 VERIFY trial of rusfertide in polycythemia vera, showing durable hematocrit control without phlebotomy eligibility and a safety profile in line with prior results.
The therapy’s multiple FDA designations, including Breakthrough Therapy and Orphan Drug, underscore its potential importance for patients who remain phlebotomy-dependent despite current standard treatments.
We’ll now...